Loading clinical trials...

Tear Cytokine Analysis as a Prediction or Diagnostic Marker in Ocular GvHD | Clinical Trials | Clareo Health

COMPLETED

Tear Cytokine Analysis as a Prediction or Diagnostic Marker in Ocular GvHD

NCT02411474•Yonsei University

Summary

Investigate the profiles of tear cytokines in patients who underwent stem cell transplantation (SCT) and attempted to determine the applicability of tear cytokines in the diagnosis of chronic graft-versus-host disease (GVHD). Evaluate tear cytokines as biomarkers of chronic ocular GVHD severity.

Eligibility

Age

20 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•The patients patients aged 20-60 years who visited the clinic 3-12 months after SCT were included in the study.

Exclusion Criteria

•The patients with histories of ocular surgery; ocular injury; and ocular diseases such as ocular infection, allergy, and autoimmune disease, as well as patients with long-term use of topical ocular medications except artificial tears.

Locations (1)

Department of Ophthalmology

Seoul, Seoul, South Korea

Key Dates

Start Date

March 1, 2014

Primary Completion Date

August 1, 2014

Completion Date

August 1, 2014

Last Updated

April 8, 2015

Enrollment

ACTUAL participants

Conditions

Chronic Graft-versus-host Disease

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

NCT06660355

Chronic Graft-versus-host Disease (cGVHD)

View study

ACTIVE_NOT_RECRUITING

Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease

NCT02611180

Acute Graft-versus-host DiseaseAcute GVHD+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 8, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Tear Cytokine Analysis as a Prediction or Diagnostic Marker in Ocular GvHD

Inclusion Criteria

Exclusion Criteria

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease

Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

A Prospective Observational Study for Evaluating CGVHD

Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children